Free Trial

Xylem (NYSE:XYL) Given New $162.00 Price Target at Stifel Nicolaus

Xylem logo with Business Services background

Xylem (NYSE:XYL - Get Free Report) had its price objective raised by research analysts at Stifel Nicolaus from $141.00 to $162.00 in a report released on Monday,Benzinga reports. The firm currently has a "buy" rating on the industrial products company's stock. Stifel Nicolaus' price objective points to a potential upside of 23.62% from the company's previous close.

Other research analysts have also issued reports about the company. JPMorgan Chase & Co. began coverage on Xylem in a research report on Friday, May 30th. They issued an "overweight" rating and a $148.00 price objective on the stock. Citigroup reiterated a "buy" rating and issued a $152.00 price objective (up from $137.00) on shares of Xylem in a research report on Monday, July 14th. Royal Bank Of Canada increased their price objective on Xylem from $143.00 to $147.00 and gave the company an "outperform" rating in a research report on Wednesday, April 30th. Robert W. Baird decreased their price objective on Xylem from $149.00 to $146.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Finally, Raymond James Financial raised Xylem to a "hold" rating in a research note on Thursday, May 15th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $149.29.

View Our Latest Research Report on XYL

Xylem Price Performance

NYSE XYL traded down $0.72 during trading hours on Monday, reaching $131.05. 237,519 shares of the company's stock were exchanged, compared to its average volume of 1,502,122. The stock has a market cap of $31.89 billion, a PE ratio of 35.24, a price-to-earnings-growth ratio of 2.38 and a beta of 1.12. Xylem has a one year low of $100.47 and a one year high of $143.50. The firm has a fifty day moving average of $128.10 and a 200-day moving average of $123.29. The company has a current ratio of 1.89, a quick ratio of 1.41 and a debt-to-equity ratio of 0.18.

Xylem (NYSE:XYL - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The industrial products company reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $0.95 by $0.08. The business had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.04 billion. Xylem had a return on equity of 10.12% and a net margin of 10.54%. Xylem's revenue for the quarter was up 1.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.90 EPS. On average, equities research analysts predict that Xylem will post 4.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Hanson & Doremus Investment Management boosted its position in Xylem by 0.9% during the second quarter. Hanson & Doremus Investment Management now owns 8,516 shares of the industrial products company's stock valued at $1,102,000 after acquiring an additional 77 shares during the last quarter. Dempze Nancy E boosted its position in Xylem by 0.3% during the fourth quarter. Dempze Nancy E now owns 25,761 shares of the industrial products company's stock valued at $2,989,000 after acquiring an additional 88 shares during the last quarter. Townsquare Capital LLC boosted its position in Xylem by 0.8% during the fourth quarter. Townsquare Capital LLC now owns 11,074 shares of the industrial products company's stock valued at $1,285,000 after acquiring an additional 88 shares during the last quarter. Center for Financial Planning Inc. boosted its position in Xylem by 52.0% during the first quarter. Center for Financial Planning Inc. now owns 266 shares of the industrial products company's stock valued at $32,000 after acquiring an additional 91 shares during the last quarter. Finally, Keel Point LLC boosted its position in Xylem by 4.1% during the fourth quarter. Keel Point LLC now owns 2,371 shares of the industrial products company's stock valued at $275,000 after acquiring an additional 93 shares during the last quarter. 87.96% of the stock is currently owned by institutional investors and hedge funds.

Xylem Company Profile

(Get Free Report)

Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.

Featured Stories

Analyst Recommendations for Xylem (NYSE:XYL)

Should You Invest $1,000 in Xylem Right Now?

Before you consider Xylem, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylem wasn't on the list.

While Xylem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started
Why Drone Stocks Are Skyrocketing Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines